Omeros is developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPARγ) agonists for the treatment and prevention of addiction to substances of abuse and other compulsive behaviors. Based on the previously unknown link between PPARγ and addictive disorders together with promising data from European pilot clinical studies and animal models of addiction, we have filed patent applications claiming the use of any PPARγ agonist, alone or in combination with other agents, for the treatment or prevention of addiction and other compulsive behaviors.

Data from our preclinical studies and pilot clinical studies suggest that a PPARγ agonist may be useful in treating and, in some cases, preventing addiction to nicotine, opioids and alcohol.

The National Institute on Drug Abuse is funding substantially all of the costs of a Phase 2 clinical study to evaluate a PPARγ agonist in the treatment of addiction to opioids. This Phase 2 clinical study is being conducted by researchers at the New York State Psychiatric Institute. We will have the right to reference the data obtained from this study for subsequent submissions to the FDA and will retain all other rights in connection with the Addiction program.

Patent Position

Omeros owns two pending U.S. patent applications and 13 pending international patent applications directed to the previously unknown link between PPARγ agonists and addictive disorders.